Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11838507 | 0.91 | HPGD (0.62) | KMT2AMEN1L3MBTL1HPGDCES1 | |
| SCHEMBL6270102 | 0.86 | MEN1 (0.61) | KMT2AMEN1L3MBTL1HPGDCES1 | |
| SCHEMBL6385964 | 0.84 | KMT2A (0.44) | KMT2AMEN1L3MBTL1HPGDCDK5 | |
| SCHEMBL6385968 | 0.84 | KMT2A (0.44) | KMT2AMEN1L3MBTL1HPGDCDK5 | |
| SCHEMBL6385244 | 0.82 | MEN1 (0.42) | KMT2AMEN1L3MBTL1HPGDCES1 | |
| SCHEMBL6385247 | 0.82 | MEN1 (0.42) | KMT2AMEN1L3MBTL1HPGDCES1 | |
| SCHEMBL9039956 | 0.80 | L3MBTL1 (0.70) | KMT2AMEN1L3MBTL1HPGDLMNA | |
| SCHEMBL2733083 | 0.79 | HPGD (0.77) | KMT2AMEN1L3MBTL1HPGDCES1 | |
| SCHEMBL1201517 | 0.79 | HPGD (0.77) | KMT2AMEN1L3MBTL1HPGDCES1 | |
| SCHEMBL1201521 | 0.79 | HPGD (0.77) | KMT2AMEN1L3MBTL1HPGDCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | MERCK SHARP & DOHME CORP. | 2011-03-17 | — | — | US | disclosed |
| US-7893071-B2 | Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893071-B2 | Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-02-22 | — | — | US | disclosed |
| WO-2009137462-A2 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065671-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | GPR119, GPR39, GPR65 | KMT2A 3444/4885MEN1 3069/4885L3MBTL1 4270/4885 |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC11 | KMT2A 30/4885MEN1 2046/4885L3MBTL1 257/4885 |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | KMT2A 30/4885MEN1 4153/4885L3MBTL1 645/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | KMT2A 30/4885MEN1 4208/4885L3MBTL1 647/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | KMT2A 47/4885MEN1 3735/4885L3MBTL1 599/4885 |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC11 | KMT2A 30/4885MEN1 2046/4885L3MBTL1 257/4885 |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | KMT2A 47/4885MEN1 3735/4885L3MBTL1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.